Additional Listing
15 September 2009
London, UK, 15 September 2009 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and siRNA delivery, announces that application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 52,000 ordinary shares of 0.5p each (the "New Ordinary Shares").
The New Ordinary Shares are being admitted pursuant to the exercise of options under the Lipoxen Plc Unapproved Share Option Plan.
It is expected that dealing in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 16 September 2009.
Enquiries:
|
Lipoxen plc
|
+44 (0)20 7691 3583
|
|
M. Scott Maguire, Chief Executive Officer
|
|
|
|
|
|
Singer Capital Markets (nominated adviser)
|
+44 (0)20 3205 7500
|
|
Jeff Keating / Claes Spång
|
|
|
|
|
|
Noble & Company
|
+44 (0) 20 7763 2200
|
|
John Llewellyn-Lloyd / Sam Reynolds
|
|
|
|
|
|
Buchanan Communications
|
+44 (0)20 7466 5000
|
|
Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye Dietrich, Catherine Breen
|
|